- AU$99.18m
- AU$86.46m
- $22.18m
- 31
- 23
- 43
- 25
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.06 | ||
| Price to Tang. Book | 6.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.92 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -110.58% | ||
| Return on Equity | -156.02% | ||
| Operating Margin | -70.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.06 | 3.44 | 8.95 | 11.71 | 22.18 | 32.84 | 40.83 | 50.8% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.
Directors
- George Savvides NEC
- Judith Mitchell CEO
- Jacqueline Butler CFO
- Jon Swanson COO
- Matthew Myntti CTO
- Dustin Haines OTH
- Bruce Hancox NED
- Mark Compton NID (60)
- Daniel Spira NID
- Aileen Stockburger NID (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 20th, 2017
- Public Since
- April 18th, 2019
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 291,695,103
- Address
- Tower B, Chatswood, 2000
- Web
- https://www.nextscience.com
- Phone
- +61 286075124
- Auditors
- KPMG
Upcoming Events for NXS
Next Science Ltd Annual Shareholders Meeting
Half Year 2024 Next Science Ltd Earnings Release
Similar to NXS
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
FAQ
What is the Next Science share price?
As of Today at 19:16 UTC, shares in Next Science are trading at AU$0.34. This share price information is delayed by 15 minutes.
How has the Next Science share price performed this year?
Shares in Next Science last closed at AU$0.34 and the price had moved by -54.97% over the past 365 days. In terms of relative price strength the Next Science share price has underperformed the ASX All Ordinaries Index by -58.05% over the past year.
What are the analyst and broker recommendations for Next Science?
The overall consensus recommendation for Next Science is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Next Science dividend yield?
Next Science does not currently pay a dividend.
Does Next Science pay a dividend?
Next Science does not currently pay a dividend.
When does Next Science next pay dividends?
Next Science does not currently pay a dividend.
How do I buy Next Science shares?
To buy shares in Next Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Next Science?
As of the previous close price of AU$0.34, shares in Next Science had a market capitalisation of AU$99.18m.
Where are Next Science shares listed?
Here are the trading details for Next Science:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NXS
What kind of share is Next Science?
Based on an overall assessment of its quality, value and momentum Next Science is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Next Science share price forecast for 2024?
The analyst consensus target price for shares in Next Science is AU$0.37. That is 8.43% above the last closing price of AU$0.34.
Analysts covering Next Science currently have a consensus Earnings Per Share (EPS) forecast of -$0.03 for the next financial year.
What is the trend in the Next Science share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Next Science. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -28.52%.
As of the last closing price of AU$0.34, shares in Next Science were trading -15.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Next Science PE Ratio?
The Next Science PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Next Science?
Next Science's management team is headed by:
- George Savvides - NEC
- Judith Mitchell - CEO
- Jacqueline Butler - CFO
- Jon Swanson - COO
- Matthew Myntti - CTO
- Dustin Haines - OTH
- Bruce Hancox - NED
- Mark Compton - NID
- Daniel Spira - NID
- Aileen Stockburger - NID